Begins Coverage on Fluidigm (NASDAQ:FLDM) started coverage on shares of Fluidigm (NASDAQ:FLDMGet Rating) in a research report report published on Friday. The firm issued a hold rating on the medical research company’s stock.

FLDM stock opened at $3.71 on Friday. The firm has a market cap of $283.76 million, a price-to-earnings ratio of -4.76 and a beta of 1.14. The company has a quick ratio of 1.03, a current ratio of 1.45 and a debt-to-equity ratio of 0.68. Fluidigm has a 12-month low of $2.67 and a 12-month high of $7.51. The company’s fifty day simple moving average is $3.62 and its 200 day simple moving average is $4.14.

Fluidigm (NASDAQ:FLDMGet Rating) last released its earnings results on Thursday, February 17th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $38.27 million during the quarter. Fluidigm had a negative net margin of 45.36% and a negative return on equity of 40.15%.

In related news, major shareholder Caligan Partners Lp acquired 200,000 shares of the business’s stock in a transaction dated Friday, April 8th. The shares were bought at an average price of $3.76 per share, with a total value of $752,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought 454,573 shares of company stock worth $1,707,613 in the last quarter. Company insiders own 2.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. raised its holdings in shares of Fluidigm by 477.4% in the 3rd quarter. Macquarie Group Ltd. now owns 11,162 shares of the medical research company’s stock worth $74,000 after acquiring an additional 9,229 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Fluidigm in the 3rd quarter worth about $75,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Fluidigm in the 1st quarter worth about $151,000. Commonwealth Equity Services LLC acquired a new stake in shares of Fluidigm in the 4th quarter worth about $60,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Fluidigm in the 4th quarter worth about $65,000. 76.59% of the stock is currently owned by institutional investors.

About Fluidigm (Get Rating)

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.

See Also

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with's FREE daily email newsletter.